Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Multidimensional Analysis of Relapsed Bone Marrow Reveals Cold Immune Microenvironment Post-TMLI in Acute Leukemia Transplant Patients

Srideshikan Sargur Madabushi, Ji Eun Lim, Yu-Lin SU, Paresh Vishwasrao, Dongyun Yang, James F. Sanchez, Sally Mokhtari, Amandeep Salhotra, Xiwei Wu, Haiqing Lee, Savita Dandapani, Ryotaro Nakamura, Raju Pillai, Marcin Kortylewski, Jeffrey Wong, MHD Monzr M. Al Malki, Anthony S. Stein, Susanta Hui

Blood (2024) 144 (Supplement 1): 775.

https://doi.org/10.1182/blood-2024-211180

Published: 2024

Journal Articles

The Microbiome and Clinical Outcome Among Patients with Multiple Myeloma (MM) Following CD38-Directed Antibody Treatment

Myo Htut, Keehoon Lee, Nitya Nathwani, Michael Rosenzweig, Murali Janakiram, Scott R. Goldsmith, James F. Sanchez, Martha Scott, Jonathan Keats, Amrita Y Krishnan, Steven T. Rosen, Sophia S. Wang

Blood (2024) 144 (Supplement 1): 1941.

https://doi.org/10.1182/blood-2024-206314

Published: 2024

Journal Articles

Tissue-Specific Myeloablative Conditioning with Total Marrow Irradiation Enhances Gut Microbiome Diversity and Mitigates Gvhd: A Novel Therapeutic Approach

Ji Eun Lim, Srideshikan Sargur Madabushi, Mengistu Lemecha Shukare, Hemendra Ghimire, Jenny Paredes, Sally Mokhtari, James F. Sanchez, Karamjeet S Sandhu, Amandeep Salhotra, Ryotaro Nakamura, Jeffrey Wong, Anthony S. Stein, Dorothy Schaue, Marcel R.M. van den Brink, MHD Monzr M. Al Malki, Guy Storme, Susanta Hui

Blood (2024) 144 (Supplement 1): 3393.

https://doi.org/10.1182/blood-2024-210774

Published: 2024

Journal Articles

A CD38-directed, single-chain T-cell engager targets leukemia stem cells through IFN-γ–induced CD38 expression

Blood (2024) 143 (16): 1599–1615.

https://doi.org/10.1182/blood.2023021570

Published: 2024

Includes: Supplemental data

Journal Articles

CD84 Is a Therapeutically Targetable Driver of Leukemogenesis Via Disruption of Energy Supply in Acute Myeloid Leukemia

Yinghui Zhu, Miso Park, Mariam Murtadha, Enrico Caserta, Le Xuan Truong Nguyen, Mahmoud Singer, Marc Denisse Estepa, Lokesh Nigam, Ada Alice Dona', James F Sanchez, Theophilus Tandoh, Man Li, Bin Zhang, Ya-Huei Kuo, Guido Marcucci, John C Williams, Flavia Pichiorri

Blood (2022) 140 (Supplement 1): 89–90.

https://doi.org/10.1182/blood-2022-170300

Published: 2022

Journal Articles

OM301, a Synthetic Polypeptide Containing the p53TA (Transactivation) Domain, Impairs Mitochondrial Activity and Survival of Myeloma Cells

Lokesh Nigam, Yinghui Zhu, Estelle Troadec, Enrico Caserta, Ada Dona', James F Sanchez, Amrita Y. Krishnan, Le Xuan Truong Nguyen, Guido Marcucci, Flavia Pichiorri

Blood (2021) 138 (Supplement 1): 2661.

https://doi.org/10.1182/blood-2021-151506

Published: 2021

Journal Articles

Total Marrow and Lymphoid Irradiation (TMLI) at a Dose of 2000cGy in Combination with Post-Transplant Cyclophosphamide (PTCy)-Based Graft Versus Host Disease (GvHD) Prophylaxis Is Safe and Associated with Favorable GvHD-Free/Relapse-Free Survival at 1 Year in Patients with Acute Myeloid Leukemia (AML)

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-141469

Published: 2020

Journal Articles

Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma

Ada Dona', PhD, Domenico Viola, Enrico Caserta, PhD, Francesca Besi, PhD, James F Sanchez, PhD, Guido Marcucci, MD, Jonathan J Keats, PhD, Amrita Y. Krishnan, MD, Matt Coffey, PhD, Douglas W. Sborov, MDMSc, Gerard Nuovo, MD, Craig C Hofmeister, MDMPH, Flavia Pichiorri, PhD

Blood (2019) 134 (Supplement_1): 1816.

https://doi.org/10.1182/blood-2019-128740

Published: 2019

Journal Articles

Phase 1 Results of Anti-PD-Ligand 1 (Durvalumab) & Lenalidomide in Patients with Cutaneous T Cell Lymphoma and Correlation with Programmed Death Ligand 1 Expression and Gene Expression Profile

Christiane Querfeld, MD PhD, Xiwei Wu, PhD, Tracy Stiller, MS, Joycelynne Palmer, PhD, James F Sanchez, PhD, Xochiquetzal Martinez, MD, Steven Rosen, MD, Jasmine Zain, MD

Blood (2019) 134 (Supplement_1): 4024.

https://doi.org/10.1182/blood-2019-126358

Published: 2019

Journal Articles

First-in-Human Imaging of Multiple Myeloma Using Copper-64-Labeled Daratumumab: Preliminary Results

Blood (2019) 134 (Supplement_1): 4394.

https://doi.org/10.1182/blood-2019-126080

Published: 2019

Journal Articles

Targeted Marrow Radiation (TMI) Improves Therapeutic Efficacy of STAT3 Decoy Molecules By Augmenting Its Delivery and Immune Modulation in an AML Mouse Model

Srideshikan Sargur Madabushi, PhD, Darren Zuro, Yu-Lin SU, PhD, Paresh Vishwasrao, MSc, Jamison Brooks, B.S, Liliana E Parra, James F Sanchez, PhD, Jeffrey Wong, MD, Marcin Kortylewski, PhD, Susanta Hui, PhD, DABR.

Blood (2019) 134 (Supplement_1): 3929.

https://doi.org/10.1182/blood-2019-127470

Published: 2019

Journal Articles

Response to Venetoclax and Hypomethylating Agents Among Prognostic Risk Groups and Genetic Subtypes of Acute Myeloid Leukemia

Ibrahim Aldoss, MD, Dongyun Yang, PhD, Raju Pillai, MD, James F Sanchez, PhD, Ahmed Aribi, MD, Haris Ali, MD, Karamjeet S Sandhu, MD, Monzr Al Malki, MD, Matthew Mei, MD, Amandeep Salhotra, MD, Samer K. Khaled, MD, Ryotaro Nakamura, MD, Weili Sun, MD PhD, Margaret R O'Donnell, MD, David S Snyder, MD, Anthony S. Stein, MD, Stephen J Forman, Guido Marcucci, Vinod A. Pullarkat, MD

Blood (2018) 132 (Supplement 1): 334.

https://doi.org/10.1182/blood-2018-99-113670

Published: 2018

Journal Articles

Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: Final Analysis of a Phase 1 Study

Michael Rosenzweig, Joycelynne Palmer, Ni-Chun Tsai, Ralf Buettner, PhD, Lupe Duarte, Myo Htut, Chatchada Karanes, Nitya Nathwani, MD, Flavia Pichiorri, PhD, Firoozeh Sahebi, Tim Synold, Xiwei Wu, James F Sanchez, Amrita Krishnan, MD, Stephen J Forman, Steven T Rosen

Blood (2018) 132 (Supplement 1): 2007.

https://doi.org/10.1182/blood-2018-99-120042

Published: 2018

Journal Articles

CD84: A Potential Novel Therapeutic Target in Multiple Myeloma

Emine Gulsen Gunes, PhD, Hadas Lewinsky, Domenico Viola, Enrico Caserta, Michael Rosenzweig, Myo Htut, James F Sanchez, PhD, Ralf Buettner, PhD, Guido Marcucci, Jonathan J Keats, PhD, Amrita Krishnan, MD, Steven T Rosen, Idit Shachar, Flavia Pichiorri, PhD

Blood (2018) 132 (Supplement 1): 1924.

https://doi.org/10.1182/blood-2018-99-119655

Published: 2018

Journal Articles

Immune Mediated Mechanisms of Resistance to Daratumumab

Domenico Viola, Ada Dona, Emine Gulsen Gunes, PhD, Estelle Troadec, Xiwei Wu, Sergio Branciamore, Tinisha McDonald, MS, Lucy Ghoda, PhD, Ashish Streatfield, James F Sanchez, PhD, Chatchada Karanes, Myo Htut, Michael Rosenzweig, Jonathan J Keats, PhD, Steven T Rosen, Guido Marcucci, Amrita Krishnan, MD, Flavia Pichiorri, PhD

Blood (2018) 132 (Supplement 1): 3201.

https://doi.org/10.1182/blood-2018-99-117441

Published: 2018

Journal Articles

Copper 64–labeled daratumumab as a PET/CT imaging tracer for multiple myeloma

Blood (2018) 131 (7): 741–745.

https://doi.org/10.1182/blood-2017-09-807263

Published: 2018

Includes: Multimedia, Supplemental data

Journal Articles

MiR- 16 Regulates Crosstalk in NF-κB Inflammatory Signaling between Myeloma Cells and Bone Marrow Macrophages

Jihane Khalife, Domenico Viola, BS, Jayeeta Ghose, Robert Weingart, James F Sanchez, Craig C Hofmeister, MDMPH, Amrita Krishnan, MD, Guido Marcucci, MD, Nadia Carlesso, MD PhD, Enrico Caserta, PhD, Flavia Pichiorri, PhD

Blood (2017) 130 (Supplement 1): 4351.

https://doi.org/10.1182/blood.V130.Suppl_1.4351.4351

Published: 2017

Journal Articles

Copper-64-Labeled Daratumumab As a PET Imaging Tracer for Multiple Myeloma: Potential Use for Minimal Residual Disease Detection

Enrico Caserta, PhD, Junie Chea, Megan Minnix, Domenico Viola, BS, Steven Vonderfecht, Jonathan J Keats, PhD, James F Sanchez, David Colcher, John E. Shively, Amrita Krishnan, MD, Flavia Pichiorri, PhD

Blood (2017) 130 (Supplement 1): 3083.

https://doi.org/10.1182/blood.V130.Suppl_1.3083.3083

Published: 2017

Journal Articles

The miRNA Profile of Cutaneous T Cell Lymphoma Correlates with the Dysfunctional Immunophenotype of the Disease

Christiane Querfeld, MD PhD, Xiwei Wu, PhD, James F Sanchez, PhD, Joycelynne M. Palmer, PhD, Azadeh Motevalli, PhD, Jasmine Zain, MD, Steven T. Rosen, MD

Blood (2016) 128 (22): 4132.

https://doi.org/10.1182/blood.V128.22.4132.4132

Published: 2016

Journal Articles

A Phase I/II Trial of Ixazomib (Ix), Pomalidomide (POM), and Dexamethasone (DEX), in Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients: Responses in Double/Triple Refractory Myeloma and Poor Risk Cytogenetics

Amrita Krishnan, Prashant Kapoor, MD, Joycelynne Palmer, PhD, Ni-Chun Tsai, MS, Shaji Kumar, MD, Sagar Lonial, MD FACP, Myo Htut, MD, Chatchada Karanes, MD, Nitya Nathwani, MD, Michael Rosenzweig, MD, Firoozeh Sahebi, MD, George Somlo, MD FACP, Lupe Duarte, CTA, Stephen J. Forman, MD, James F Sanchez, PhD, Jesus G. Berdeja, MD

Blood (2016) 128 (22): 3316.

https://doi.org/10.1182/blood.V128.22.3316.3316

Published: 2016

NARROW

Multidimensional Analysis of Relapsed Bone Marrow Reveals Cold Immune Microenvironment Post-TMLI in Acute Leukemia Transplant Patients

The Microbiome and Clinical Outcome Among Patients with Multiple Myeloma (MM) Following CD38-Directed Antibody Treatment

Tissue-Specific Myeloablative Conditioning with Total Marrow Irradiation Enhances Gut Microbiome Diversity and Mitigates Gvhd: A Novel Therapeutic Approach

A CD38-directed, single-chain T-cell engager targets leukemia stem cells through IFN-γ–induced CD38 expression

CD84 Is a Therapeutically Targetable Driver of Leukemogenesis Via Disruption of Energy Supply in Acute Myeloid Leukemia

OM301, a Synthetic Polypeptide Containing the p53TA (Transactivation) Domain, Impairs Mitochondrial Activity and Survival of Myeloma Cells

Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma

Phase 1 Results of Anti-PD-Ligand 1 (Durvalumab) & Lenalidomide in Patients with Cutaneous T Cell Lymphoma and Correlation with Programmed Death Ligand 1 Expression and Gene Expression Profile

First-in-Human Imaging of Multiple Myeloma Using Copper-64-Labeled Daratumumab: Preliminary Results

Targeted Marrow Radiation (TMI) Improves Therapeutic Efficacy of STAT3 Decoy Molecules By Augmenting Its Delivery and Immune Modulation in an AML Mouse Model

Response to Venetoclax and Hypomethylating Agents Among Prognostic Risk Groups and Genetic Subtypes of Acute Myeloid Leukemia

Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: Final Analysis of a Phase 1 Study

CD84: A Potential Novel Therapeutic Target in Multiple Myeloma

Immune Mediated Mechanisms of Resistance to Daratumumab

Copper 64–labeled daratumumab as a PET/CT imaging tracer for multiple myeloma

MiR- 16 Regulates Crosstalk in NF-κB Inflammatory Signaling between Myeloma Cells and Bone Marrow Macrophages

Copper-64-Labeled Daratumumab As a PET Imaging Tracer for Multiple Myeloma: Potential Use for Minimal Residual Disease Detection

The miRNA Profile of Cutaneous T Cell Lymphoma Correlates with the Dysfunctional Immunophenotype of the Disease

A Phase I/II Trial of Ixazomib (Ix), Pomalidomide (POM), and Dexamethasone (DEX), in Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients: Responses in Double/Triple Refractory Myeloma and Poor Risk Cytogenetics

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only